Alcon AG (ALC)
Alcon - Alcon Announces U.S. Launch of TRYPTYR (acoltremon ophthalmic solution) 0.003%, a New Prescription Treatment Option for Millions of Dry Eye Sufferers
ProPhase Labs Inc. (PRPH)
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
bioAffinity Technologies Inc. (BIAFW)
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
Johnson & Johnson (JNJ)
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
SOBR Safe, Inc. (SOBR)
SOBRsafe Achieves Technology Milestone with Strong Core Sensing Capabilities in Third-Party Validation Results
Urogen Pharma Inc (URGN)
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
Dare Bioscience Inc. (DARE)
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
Immutep Limited (IMMP)
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Recursion Pharmaceuticals Inc (RXRX)
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
AstraZeneca Plc (AZNCF)
Hoth Therapeutics Inc (HOTH)
Hoth Therapeutics Notification (HOTH)
Cel-Sci Corporation (CVM)
DURECT Corporation (DRRX)
Simulations Plus Inc (SLP)
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design